Bispecific antibody based therapeutics: Strengths and challenges

Blood Reviews
Archana ThakurLawrence G Lum

Abstract

Monoclonal antibody-based targeted therapy has greatly improved treatment options for patients. However, long-term efficacy of such antibodies is limited by resistance mechanisms. New insights into the mechanisms by which tumors evade immune control have driven innovative therapeutic strategies to eliminate cancer by re-directing immune cells to tumors. Advances in protein engineering technology have generated multiple bispecific antibody (BsAb) formats capable of targeting multiple antigens as a single agent. Approval of two BsAb and three check point blocking mAbs represent a paradigm shift in the use of antibody constructs. Since BsAbs can directly target immune cells to tumors, drug resistance and severe adverse effects are much reduced. The wave of next generation "bispecific or multispecific antibodies" has advanced multiple candidates into ongoing clinical trials. In this review, we focus on preclinical and clinical studies in hematological malignancies as well as discuss reasons for the limited success of BsAbs against solid tumors.

Citations

Jun 19, 2019·Bioanalysis·Sophie Tourdot, Timothy P Hickling
Mar 20, 2019·Journal of Immunology Research·Shixue ChenLei Zhao
May 10, 2019·Frontiers in Oncology·Reena GoswamiVenkaiah Betapudi
Oct 23, 2019·Signal Transduction and Targeted Therapy·Dan LiWei Wang
Dec 24, 2019·Cancer Control : Journal of the Moffitt Cancer Center·Fabio CofanoDiego Garbossa
Feb 6, 2019·Therapeutic Advances in Hematology·Laurens E FranssenNiels W C J van de Donk
May 28, 2020·Frontiers in Immunology·Margaux LejeuneJo Caers
Apr 22, 2020·Cellular & Molecular Immunology·Heliang LiErwei Song
Feb 25, 2019·Journal of Cancer Research and Clinical Oncology·Lin Yu, Jianhua Wang
Oct 23, 2020·Physics in Medicine and Biology·Damijan Valentinuzzi, Robert Jeraj
Nov 17, 2020·International Journal of Biological Macromolecules·Seyed Samad HosseiniMichael R Hamblin
Jan 29, 2021·Military Medical Research·Yi Fang, Jian Hou
Jan 16, 2021·Journal of Experimental & Clinical Cancer Research : CR·Chiara ModicaElisa Vigna
Dec 17, 2019·Current Opinion in Biotechnology·Christoph Rader
Sep 20, 2020·Signal Transduction and Targeted Therapy·Dan LiWei Wang
May 1, 2021·Cancers·Cecilia Nakid-CorderoVincent Vieillard
May 1, 2021·Antibody Therapeutics·Jing ZhangPengfei Zhou
Apr 24, 2021·Trends in Endocrinology and Metabolism : TEM·Thomas SiffAzeddine Atfi
May 4, 2021·Current Hematologic Malignancy Reports·Melanie SchwerdtfegerSebastian Kobold
May 5, 2021·Journal of Hematology & Oncology·Zheng TianXin Wang
May 15, 2021·Frontiers in Pharmacology·Hanyi FangBernadette Marquez-Nostra
May 28, 2021·Biomarker Research·Shujie ZhouJinming Yu
Jun 26, 2021·Pharmacology & Therapeutics·Yiming JinAndrew J Wiemer
Aug 26, 2021·EMBO Molecular Medicine·Shuhang WangNing Li
Aug 28, 2021·Antibodies·Ramachandran MuraliMark Greene
Dec 8, 2021·Frontiers of Medicine·Hongyun ZhaoRui-Hua Xu
Dec 9, 2021·Clinical & Experimental Metastasis·Inderjit Mehmi, Omid Hamid

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Antigenic Modulation

Antigenic modulation occurs when an antibody cross-links antigens on a cell surface, causing the antigens to become internalized. This can lead to therapeutic failure of monoclonal antibodies as the expression of the antigen becomes decreased on target cells. Find the latest research on antigenic modulation here.

Related Papers

Expert Review of Clinical Pharmacology
Jijie Gu, Tariq Ghayur
Journal of Hematology & Oncology
Shengnan YuKongming Wu
Current Opinion in Drug Discovery & Development
Patrick Chames, Daniel Baty
Nature Reviews. Cancer
Andrew M ScottLloyd J Old
© 2022 Meta ULC. All rights reserved